港股异动 | 3D MEDICINES(01244)涨超4% 恩维达®治疗非MSI-H/非dMMR晚期子宫内膜癌适应症纳入突破性治疗药物

智通财经2023-11-30

智通财经APP获悉，3D MEDICINES(01244)涨超4%，截至发稿，涨4.13%，报8.83港元，成交额1031.39万港元。消息面上，3D Medicines近日宣布，CDE官网公示其皮下注射抗PD-L1抗体恩维达®（恩沃利单抗注射液）拟纳入突破性治疗药物，拟定适应症为：联合多靶点受体酪氨酸激酶（RTK）抑制剂仑伐替尼治疗既往至少一线含铂化疗失败或不能耐受的非微卫星高度不稳定（MSI-...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2387041895?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-11-30 15:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2387041895","market":"hk","top_or_hot":-1,"title":"港股异动 | 3D MEDICINES(01244)涨超4% 恩维达®治疗非MSI-H/非dMMR晚期子宫内膜癌适应症纳入突破性治疗药物","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，3D MEDICINES(01244)涨超4%，截至发稿，涨4.13%，报8.83港元，成交额1031.39万港元。消息面上，3D Medicines近日宣布，CDE官网公示其皮下注射抗PD-L1抗体恩维达®（恩沃利单抗注射液）拟纳入突破性治疗药物，拟定适应症为：联合多靶点受体酪氨酸激酶（RTK）抑制剂仑伐替尼治疗既往至少一线含铂化疗失败或不能耐受的非微卫星高度不稳定（MSI-...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1031435.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 3D MEDICINES(01244)涨超4% 恩维达®治疗非MSI-H/非dMMR晚期子宫内膜癌适应症纳入突破性治疗药物</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 3D MEDICINES(01244)涨超4% 恩维达®治疗非MSI-H/非dMMR晚期子宫内膜癌适应症纳入突破性治疗药物\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-11-30 15:18 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1031435.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，3D MEDICINES(01244)涨超4%，截至发稿，涨4.13%，报8.83港元，成交额1031.39万港元。消息面上，3D Medicines近日宣布，CDE官网公示其皮下注射抗PD-L1抗体恩维达®（恩沃利单抗注射液）拟纳入突破性治疗药物，拟定适应症为：联合多靶点受体酪氨酸激酶（RTK）抑制剂仑伐替尼治疗既往至少一线含铂化疗失败或不能耐受的非微卫星高度不稳定（MSI-...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1031435.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1992135472.HKD","symbol_name":"ALLIANZ GLOBAL INTELLIGENT CITIES \"AT\" (HKD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1031435.html","article_id":"2387041895","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2387041895","pubTimestamp":1701328736,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"公司表示，本次拟将恩维达治疗非MSI-H/非dMMR晚期子宫内膜癌适应症纳入突破性治疗品种纳入将有助于缩短对于该适应症的审批时间及商业化过程。据悉，恩维达上市以来，已披露销售额为9.8亿元人民币，覆盖全国30个省，200多个城市，帮助数万计肿瘤患者。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1992135472.HKD":"ALLIANZ GLOBAL INTELLIGENT CITIES \"AT\" (HKD) ACC","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK4020":"通信设备","LU1992135399.USD":"Allianz Global Intelligent Cities AT Acc USD","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","01244":"3D MEDICINES","LU2272731782.SGD":"Allianz Global Intelligent Cities AM Dis H2-SGD","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","MSI":"摩托罗拉解决方案","BK1161":"生物科技","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","BK4585":"ETF&股票定投概念","LU2272731600.USD":"Allianz Global Intelligent Cities AM Dis USD","BK4588":"碎股"},"translate_title":"Hong Kong stock changes 3D MEDICINES (01244) rose by more than 4%. The indications of Enweida ® for the treatment of non-MSI-H/non-dMMR advanced endometrial cancer were included in breakthrough treatment drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01244":1,"MSI":1},"content_text":"智通财经APP获悉，3D MEDICINES(01244)涨超4%，截至发稿，涨4.13%，报8.83港元，成交额1031.39万港元。消息面上，3D Medicines近日宣布，CDE官网公示其皮下注射抗PD-L1抗体恩维达®（恩沃利单抗注射液）拟纳入突破性治疗药物，拟定适应症为：联合多靶点受体酪氨酸激酶（RTK）抑制剂仑伐替尼治疗既往至少一线含铂化疗失败或不能耐受的非微卫星高度不稳定（MSI-H）/非错配修复基因缺陷型（dMMR）晚期子宫内膜癌。公司表示，本次拟将恩维达®治疗非MSI-H/非dMMR晚期子宫内膜癌适应症纳入突破性治疗品种纳入将有助于缩短对于该适应症的审批时间及商业化过程。据悉，恩维达®上市以来，已披露销售额为9.8亿元人民币，覆盖全国30个省，200多个城市，帮助数万计肿瘤患者。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2387041895"}